Study guide

4.3 Unstageable, DTPI, MDRPI, and Mucosal Injuries

WOCNCB Certified Wound Care Nurse CWCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CWCN Exam Facts 1.2 Eligibility: Traditional, Experiential, and WTA-C Credit 1.3 Fees, Retakes, Recertification, and Test Strategy

2 Skin Biology, History & Systemic Factors

2.1 Integumentary Anatomy and Skin Barrier 2.2 Healing Phases, Healing vs Non-Healing, and Biofilm 2.3 History, Psychosocial Factors, Nutrition, and Pain 2.4 Systemic Healing Factors and Medications

3 Diagnostics and the Focused Wound Exam

3.1 Vascular, Laboratory, Imaging, and Perfusion Studies 3.2 Wound Measurement, Periwound Signs, and Dermatologic Differentials 3.3 When and How to Culture a Wound

4 Pressure Injury Pathophysiology and Staging

4.1 Pressure Injury Pathophysiology and Risk Tools 4.2 NPIAP Stages 1 through 4 4.3 Unstageable, DTPI, MDRPI, and Mucosal Injuries

5 Lower-Extremity and Special Etiologies

5.1 Venous / LEVD Ulcer Assessment 5.2 Arterial / LEAD Ulcer Assessment and PAD Testing 5.3 Neuropathic Foot Ulcers, Charcot, and Wagner Grading 5.4 Mixed Disease, Atypical, Surgical, Traumatic, and Burn Wounds

6 Prevention and Support Surfaces

6.1 Risk-Based Prevention: Moisture, Nutrition, Mobility, Cognition 6.2 Repositioning, Shear Reduction, and Seating 6.3 Support Surface Types and Selection

7 Offloading, Moisture, and Skin Products

7.1 Offloading and Protective Footwear 7.2 MASD/IAD, MARSI Prevention, and Skin Care Products 7.3 Friction, Heel Protection, and Preventing Treatment Complications

8 Wound-Care Principles, Pain, and Studies

8.1 Moisture Balance, Dead Space, and Periwound Protection 8.2 Recommending Pain Management Modalities 8.3 Obtaining Cultures and Recommending Studies

9 Cleansing and Wound Bed Preparation

9.1 Wound Cleansing Regimens 9.2 TIME: Infection, Moisture, and Edge Optimization 9.3 Chemical Cauterization Indications

10 Debridement Modalities

10.1 Debridement Types, Indications, and Contraindications 10.2 Conservative Sharp vs Surgical/Excisional Debridement 10.3 Autolytic, Enzymatic, Biological, and Mechanical Debridement

11 Topical Therapies

11.1 Hydrating Dressings: Hydrogels, Films, Hydrocolloids 11.2 Absorbent Dressings: Foams, Alginates, Hydrofibers 11.3 Antimicrobials, Odor Control, and Periwound Integrity

12 Compression Therapy

12.1 Compression Types, Indications, and Contraindications 12.2 Static vs Dynamic Compression Application 12.3 Mixed Arterial-Venous Disease and Compression Safety

13 Advanced and Adjunctive Therapies

13.1 Negative Pressure Wound Therapy 13.2 HBOT, Bioengineered Tissue, and Leech Therapy 13.3 Hydrotherapy, Pulsed Lavage, Mist, Maggot Therapy, and Total Contact Casting

14 Patient-Centered Goals

14.1 Patient-Centered Care, Access, and Cultural Beliefs 14.2 Preventive, Palliative, Maintenance, and Curative Goals 14.3 Writing Patient-Focused Skin and Wound Goals

15 Evaluation, Modification, and Documentation

15.1 Evaluating Treatment Effectiveness 15.2 Interpreting Response and Modifying the Plan 15.3 Documentation, CMS Quality Context, and Surveillance

16 Patient and Caregiver Education

16.1 Health Literacy, Goals, and Teach-Back 16.2 Educating on Procedures, Skin Care, and Diagnostic Results 16.3 Modifiable Risk Factors and Resource Access

17 Educating Other Clinicians

17.1 Teaching Skin and Wound Principles, Procedures, and Goals 17.2 Infection Control, Repositioning, Moisture, Nutrition, and Trauma Avoidance for Teams 17.3 Recommending Non-Invasive and Invasive Next Steps

18 Collaboration, Referral, and Handoff

18.1 Support, Supply Access, Post-Acute Care, and Service Referrals 18.2 Referring for Studies and Specialty Consults 18.3 Handoff Communication Across Settings

4.3 Unstageable, DTPI, MDRPI, and Mucosal Injuries

Key Takeaways Explain This Topic AI

Unstageable pressure injury is full-thickness loss whose base is hidden by slough or eschar; after the base is visible, restage as Stage 3 or Stage 4.

Do not remove stable, dry, intact eschar on an ischemic heel or ischemic limb unless infection or fluctuance is present; that eschar is a physiologic dressing.

DTPI is persistent non-blanchable deep red, maroon, or purple intact skin or a blood-filled blister from pressure and shear; it is not Stage 1 and not a bruise, and it may evolve.

When a device injures keratinized skin, stage with the same cutaneous categories and name the device (NGT, oxygen tubing, casts, restraints, stockings, tracheostomy ties).

Mucosal membrane pressure injuries (endotracheal tube, fecal-management tube, and similar devices) are not given NPIAP numeric stages 1 through 4; document mucosal pressure injury and the device.

Last updated: September 2026

Unstageable, DTPI, MDRPI, and Mucosal Injuries

Numeric stages 1 through 4 assume you can see the relevant anatomy on keratinized skin . Four additional categories prevent dangerous guesswork: unstageable pressure injury, deep tissue pressure injury (DTPI) , medical device-related pressure injury (MDRPI) , and mucosal membrane pressure injury . NPIAP category names are the classification system used in practice; using those names in this ExamFinch section is not a sponsorship claim.

Unstageable: full-thickness whose base you cannot see

An unstageable pressure injury is full-thickness skin and tissue loss in which the extent of damage cannot be confirmed because it is obscured by slough or eschar. You know it is at least full-thickness; you cannot yet say whether it is Stage 3 or Stage 4. Do not pick a number to satisfy a computer field.

Once slough or eschar is removed and the base is visible, restage as Stage 3 or Stage 4 . That is not reverse-staging; it is finishing an incomplete assessment. If debridement is not performed, the wound remains unstageable. A shrinking surface of eschar still does not become Stage 2.

Stable eschar on an ischemic heel or ischemic limb

Do not remove stable, dry, intact eschar on an ischemic heel or ischemic limb when there is no erythema, fluctuance, or drainage. That eschar functions as a physiologic dressing . Softening or sharp debridement of a dry ischemic heel can convert a closed, poorly perfused covering into an open wound that will not heal.

Debride, or refer for debridement, when there are signs of infection or instability: fluctuance, advancing erythema, drainage, odor, or systemic signs pointing to the wound. Facility and vascular-team protocols govern the method; the exam point is the exception, not a license to ignore infection.

Eschar situation Action Staging

Dry, intact, adherent heel eschar, no fluctuance, ischemic limb Leave stable eschar; protect and offload Unstageable while the base is hidden

Heel eschar with fluctuance, drainage, or surrounding infection Debridement indicated After the base is visible, Stage 3 or Stage 4

  • Sacral wound with loose slough you can safely remove Debride per plan of care Then Stage 3 or Stage 4
  • Purple intact skin, no slough Not unstageable Consider DTPI
  • Scenario: the request to peel a dry heel

A consulting nurse is asked to stage and debride a dry, black, firmly adherent heel plaque in a patient with non-palpable pedal pulses and no periwound erythema. The correct action is to document an unstageable pressure injury, protect the eschar, offload the heel, and involve vascular assessment—not to unroof a stable ischemic covering.

Deep tissue pressure injury

DTPI is persistent non-blanchable deep red, maroon, or purple discoloration of intact skin, or a blood-filled blister , from intense and/or prolonged pressure and shear. The area may be painful, firm, mushy, boggy, warmer, or cooler than adjacent tissue. Epidermal separation can reveal a dark wound bed.

Key contrasts:

Not Stage 1. Stage 1 is non-blanchable erythema or a persistent lighter color change of intact skin, not deep purple or maroon over a loaded prominence.

Not a bruise. DTPI has a pressure-and-shear history over a loaded area. Anticoagulation ecchymoses and trauma hematomas are different etiologies; do not label every purple patch DTPI.

It may evolve. DTPI can resolve without tissue loss, or it can declare itself as a Stage 3, Stage 4, or unstageable wound as necrosis demarcates. Document what you see now and the evolution; do not reverse-stage later findings into a smaller number.

Purple intact skin over a bony prominence after unrelieved load is DTPI until a better explanation exists. Waiting for it to become a Stage 2 wastes the window for offloading.

Scenario: the stretcher purple heel

After 11 hours in the emergency department, a patient's lateral heel is intact but persistently purple and cooler than the contralateral heel. This is DTPI, not Stage 1 and not a bruise from a blood-pressure cuff. Offload immediately and watch for evolution.

Loading diagram... Pressure injury staging decision flow

Medical device-related pressure injury

MDRPI results from a diagnostic or therapeutic device. The injury often conforms to the pattern or shape of the device . When keratinized skin is involved, stage with the same cutaneous NPIAP categories (Stage 1 through 4, unstageable, or DTPI) and document the device . Staging the skin and naming the hardware are both required; one does not replace the other.

Devices to inspect on every skin check:

  • Nasogastric tubes (ala nasi, naris, columella)
  • Oxygen tubing and masks (ears, nasal bridge, cheeks)
  • Casts, splints, and traction
  • Restraints
  • Antiembolism stockings and sequential-compression sleeves
  • Tracheostomy ties and ventilator tubing
  • Pulse-oximetry probes and blood-pressure cuffs
  • Cervical collars and immobilizers

Device-related injury can occur without an underlying bony prominence. The device is the concentrating object. Contrast that with classic pressure over bone from body weight against a mattress or chair. Both are pressure injuries; only MDRPI requires naming the hardware. Pathophysiology is still deformation, ischemia, reperfusion, and microclimate—the mask strap can create heat and moisture under plastic while it also compresses the nasal bridge.

Mucosal membrane pressure injuries: do not assign Stages 1 through 4

Mucous membrane (lip, mouth, nose, urethra, vagina, rectum) does not have the same keratinized epidermis-to-subcutaneous anatomy that numeric stages describe. Do not stage mucosal membrane pressure injuries with NPIAP Stages 1 through 4 , and do not call them unstageable as a workaround number. Document a mucosal membrane pressure injury and name the device.

Typical devices include endotracheal tubes, nasotracheal tubes, bite blocks, nasogastric tubes where they contact mucosa, fecal-management systems, and urinary catheters. A lip ulcer under an endotracheal-tube holder is a mucosal (or mucocutaneous) device-related pressure injury—not Stage 2 because mucosa is thin, and not Stage 1 because the surface is not keratinized intact skin in the Stage 1 sense.

  • Location Staging rule Documentation must include
  • Keratinized skin under a device Use cutaneous stages, DTPI, or unstageable Device name and cutaneous category
  • Mucosa under a device No numeric stage Mucosal membrane pressure injury plus device
  • Skin over a bony prominence, no device Cutaneous stages Site and stage; never reverse-stage

After you classify, record location, size, undermining, tunneling, exudate, wound bed, edge, periwound, pain, and the device if one exists. Classification is necessary; it is not the entire wound assessment.

Scenario: endotracheal tube versus sacral bone

Two findings on the same ventilated patient: a linear ulcer of the lip under the endotracheal-tube tape, and a full-thickness sacral wound with visible adipose and no fascia. The lip finding is a mucosal membrane pressure injury related to the airway device—no Stage 2. The sacrum is a Stage 3 pressure injury related to bed load. Mixing those labels is a common exam trap: device on mucosa does not get a number; device on skin would be staged and named; pressure over bone is staged without inventing a device.

Work the decision flow the same way every time: mucosa first (no number), then whether a device is on skin (name it, then stage), then intact purple versus erythema versus open depth, then whether the base is hidden. That sequence prevents reverse-staging, prevents numbering mucosa, and prevents calling purple intact skin Stage 1.